Financial Performance - Fourth-quarter 2024 total net sales were $667.5 million, a decrease of 2.0% compared to $681.2 million in Q4 2023[4] - Full-year 2024 reported net sales decreased 3.9% to $2,566.5 million compared to $2,671.2 million in 2023[12] - Bio-Rad reported net sales of $667.5 million for Q4 2024, a decrease of 2.3% from $681.2 million in Q4 2023[37] - For the full year 2024, Bio-Rad's revenues totaled $2.566 billion, down from $2.671 billion in 2023, marking a decline of 3.9%[37] Segment Performance - Life Science segment net sales for Q4 2024 were $275.0 million, a decline of 5.5% year-over-year, driven by weakness in biotech and biopharma markets[5] - Clinical Diagnostics segment net sales for Q4 2024 were $392.5 million, an increase of 0.9% compared to Q4 2023, primarily due to increased demand for quality control and blood typing products[6] Profitability Metrics - Full-year 2024 gross margin was 53.7%, compared to 53.4% in 2023[14] - Non-GAAP gross margin for full-year 2024 was 55.0%, compared to 54.2% in 2023[17] - GAAP gross profit for Q4 2024 was $342.0 million, representing 51.2% of revenue, compared to $366.3 million and 53.8% in Q4 2023[45] - Non-GAAP gross profit for the year ended December 31, 2024, was $1,411.6 million, or 55.0% of revenue, compared to $1,448.3 million and 54.2% in 2023[45] Income and Loss - The company experienced a net loss of $715.8 million in Q4 2024, compared to a net income of $349.7 million in Q4 2023, resulting in a basic loss per share of $25.57[37] - GAAP net income for the period was $(715.8) million, a decrease of 107.2% compared to the previous year[48] - The company reported a significant loss of $(1,844.2) million in GAAP net income for the year, a decrease of 71.9%[48] - Non-GAAP net income was $81.2 million, representing a 12.2% margin, while the previous year's figure was $89.3 million with a 13.1% margin[48] Expenses - Research and development expenses increased to $79.6 million in Q4 2024, up from $63.9 million in Q4 2023, reflecting a growth of 24.5%[37] - GAAP research and development expense for Q4 2024 was $79.6 million, up from $63.9 million in Q4 2023[46] - Non-GAAP research and development expense for the year ended December 31, 2024, was $281.8 million, compared to $254.8 million in 2023[46] - GAAP selling, general and administrative expense for Q4 2024 was $204.0 million, slightly down from $207.1 million in Q4 2023[45] - Non-GAAP selling, general and administrative expense for the year ended December 31, 2024, was $798.5 million, compared to $814.6 million in 2023[45] Cash Flow and Assets - Cash and cash equivalents at the end of 2024 were $488.1 million, an increase from $403.8 million at the end of 2023[40] - Total assets decreased to $9.364 billion in 2024 from $12.299 billion in 2023, a decline of 23.6%[40] - The company reported cash provided by operating activities of $455.2 million for the year ended December 31, 2024, compared to $374.9 million in 2023, an increase of 21.4%[42] Future Outlook - The company expects non-GAAP, currency-neutral revenue growth of approximately 1.5% to 3.5% for full-year 2025[20] - The company expects continued focus on market expansion and new product development in the upcoming quarters[46] - The anticipated acquisition of Stilla Technologies is expected to further Bio-Rad's planned transformation and commercial excellence[34] - Forecasted non-GAAP operating margin for 2025 excludes 87 basis points related to amortization of purchased intangibles[51] - The company noted that future financial expectations are subject to significant uncertainty and cannot be reasonably predicted[51] Tax and Liabilities - The effective tax rate for full-year 2024 was 21.3%, down from 25.0% in 2023[16] - Bio-Rad's total liabilities decreased to $2.794 billion in 2024 from $3.558 billion in 2023, a reduction of 21.5%[40] Acquisition and Restructuring Costs - Bio-Rad announced the intent to acquire Stilla Technologies, a digital PCR developer, expected to close by the end of Q3 2025[22] - The company incurred acquisition-related costs of $11.7 million and restructuring costs of $14.7 million during the reporting period[48]

Company Overview - Bio-Rad Laboratories (BIO) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended December 2024 [1] - The earnings report is scheduled for release on February 13, 2025, and could influence the stock price depending on whether the results meet or exceed expectations [2] Earnings Estimates - The Zacks Consensus Estimate predicts quarterly earnings of $2.92 per share, reflecting a year-over-year decrease of 5.8% [3] - Expected revenues are $674.71 million, which is a 1% decline from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 0.22% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10] - Bio-Rad's Earnings ESP is currently at -2.06%, suggesting a lower Most Accurate Estimate compared to the Zacks Consensus Estimate [11] Earnings Surprise History - In the last reported quarter, Bio-Rad exceeded expectations by delivering earnings of $2.01 per share against an expected $1.28, resulting in a surprise of +57.03% [12] - Over the past four quarters, the company has consistently beaten consensus EPS estimates [13] Market Sentiment - Despite the historical ability to beat estimates, the current combination of a negative Earnings ESP and a Zacks Rank of 2 (Buy) complicates predictions for the upcoming earnings report [11][16] - The company does not appear to be a compelling candidate for an earnings beat based on current indicators, but other factors should also be considered by investors [16]

Company Overview - Bio-Rad Laboratories (BIO) is part of the Medical sector, which includes 1013 individual stocks and currently holds a Zacks Sector Rank of 4 [2] - The Zacks Rank for Bio-Rad Laboratories is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Metrics - The Zacks Consensus Estimate for Bio-Rad's full-year earnings has increased by 0.7% over the past quarter, reflecting stronger analyst sentiment and an improving earnings outlook [4] - Year-to-date, Bio-Rad has gained approximately 7.5%, outperforming the average return of 5.7% for Medical companies [4] - In the Medical - Products industry, which includes 83 stocks, Bio-Rad is ranked 140 and has slightly underperformed its industry, which has gained an average of 9.8% this year [6] Comparative Analysis - Certara, Inc. (CERT) is another Medical stock that has outperformed the sector with a year-to-date return of 31.3% and a Zacks Rank of 2 (Buy) [5] - Certara belongs to the Medical - Biomedical and Genetics industry, which is ranked 68 and has increased by 4.5% this year [6] Investment Outlook - Both Bio-Rad Laboratories and Certara, Inc. are highlighted as stocks to watch for investors interested in the Medical sector due to their solid performance [7]

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix will present at the 2025 BIO CEO & Investor Conference on February 11, 2025, at 10:15 AM EST [1][2] - The company will provide a corporate overview and participate in one-on-one meetings with registered investors during the conference [2][3] - Protalix's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets [5] - Key product candidates include PRX–115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout, and PRX–119, a plant cell-expressed long-action DNase I for NETs-related diseases [5]

CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY. Details regarding Lifecore’s participation are as follows: 2025 BIO CEO & Investor ConferenceDetails: Lifecore management, including Paul Josephs, chief executive o ...

Bio-Rad Laboratories, Inc.’s (BIO) solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees increased demand for quality control products, boosting its growth. Furthermore, the company’s emphasis on international expansion bodes well.  Yet, a soft Biopharma segment and macro-driven pressures on Bio-Rad’s margins raise worries.In the past year, shares of this Zacks Rank #2 (Buy) company have soared 13.3% compar ...

MINNEAPOLIS, Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas.Bio-Techne will feature its cell and gene therapy workflow reproducibility and scalability solutions, including ...

MINNEAPOLIS, Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen brands across Turkey.Founded in the late 2000s, MedSanTek is a leading in vitro diagnosti ...

HOLMDEL, N.J., Dec. 02, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless, and phish-resistant authentication experiences, today announced it has entered into an agreement with Fiber Food Systems, Inc. (“Fiber”), an innovative company with focus on global food security, developing innovation food-technology, and p ...

MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences ...